We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.86%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.54B
AUM Growth
+$74.3M
Cap. Flow
-$104M
Cap. Flow %
-2.3%
Top 10 Hldgs %
49.79%
Holding
155
New
7
Increased
39
Reduced
61
Closed
13

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$37.9M
2
AKRO
Akero Therapeutics
AKRO
+$33.4M
3
BPMC
Blueprint Medicines
BPMC
+$29.6M
4
TMO icon
Thermo Fisher Scientific
TMO
+$20.6M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$19.4M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$33M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.4M
3
ISRG icon
Intuitive Surgical
ISRG
+$24.6M
4
BSX icon
Boston Scientific
BSX
+$18.8M
5
COR icon
Cencora
COR
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Technology 0.01%
3 Consumer Discretionary 0.01%
4 Communication Services 0.01%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNY icon
151
Sanofi
SNY
$107B
– –
-16,000
Closed -$887K
SRPT icon
152
Sarepta Therapeutics
SRPT
$1.82B
– –
-149,113
Closed -$9.52M
THC icon
153
Tenet Healthcare
THC
$16.8B
– –
-94,722
Closed -$12.7M
ZLAB icon
154
Zai Lab
ZLAB
$2.28B
– –
-20,000
Closed -$723K
ASTH icon
155
Astrana Health
ASTH
$2.23B
– –
-163,155
Closed -$5.06M
3 4 5 6
7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2025 Portfolio in Review

As of Q2 2025, Bellevue Group held 155 positions worth $4.54B, up 1.7% from $4.46B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group's Q2 2025 filing shows 7 new, 39 increased, 61 reduced and 13 closed positions. Its largest new stake was Blueprint Medicines: 284,900 shares worth $36.5M. The largest sale was Incyte, an estimated $33M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Bellevue Group's largest Q2 2025 buy was Blueprint Medicines: 284,900 shares worth $36.5M.
  • Bellevue Group added most to Immunocore in Q2 2025, an estimated $37.9M increase.
  • Bellevue Group's biggest Q2 2025 reduction was Incyte, cutting an estimated $33M.
  • Bellevue Group fully exited Bruker in Q2 2025, selling an estimated $14M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.54B portfolio in Q2 2025.
  • Bellevue Group opened 7 new positions and closed 13 in Q2 2025.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $4.54B.

Based on Bellevue Group's 13F filing for Q2 2025, filed 14 Aug 2025.